HD-TAC7

• CAT Number: I043552
• Molecular Formula: C33H32FN7O7
• Molecular Weight: 657.65
• Purity: ≥95%
• Synonyms: N-(2-amino-4-fluorophenyl)-4-[5-[[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetyl]amino]pentanoylamino]benzamide
• InChI: InChI=1S/C33H32FN7O7/c34-19-9-12-23(22(35)16-19)39-30(45)18-7-10-20(11-8-18)38-26(42)6-1-2-15-36-28(44)17-37-24-5-3-4-21-29(24)33(48)41(32(21)47)25-13-14-27(43)40-31(25)46/h3-5,7-12,16,25,37H,1-2,6,13-15,17,35H2,(H,36,44)(H,38,42)(H,39,45)(H,40,43,46)
• InChIKey: AMBNMDIPGZXRRW-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCC(=O)NCCCCC(=O)NC4=CC=C(C=C4)C(=O)NC5=C(C=C(C=C5)F)N

HD-TAC7（Cat No.:I043552）is a chemical compound that acts as a selective histone deacetylase (HDAC) inhibitor. HDACs are enzymes that regulate gene expression by removing acetyl groups from histones, which affects chromatin structure and cellular processes. By inhibiting HD-TAC7, it promotes the acetylation of histones, leading to the activation of tumor suppressor genes and cell cycle regulation. This mechanism makes HD-TAC7 a potential therapeutic agent in cancer research, particularly in hematologic malignancies and solid tumors. It may also have applications in other diseases where HDAC activity is dysregulated, such as neurodegenerative disorders.